Potential early warning system for lung cancer identified.

October 10, 2007

An immune system protein could act as an early warning system for lung cancer, reveals research published ahead of print in the journal Thorax.

Lung cancer kills around 900,000 people every year, and can take 20 years or more to develop fully. But it is usually only picked up at an advanced stage, when the chances of successful treatment are slim.

As yet, there is no effective early warning system to detect the disease in its early treatable stages, and the dismal long term prospects of patients with lung cancer have changed little in the past 30 years.

The research team analysed blood (plasma) samples from 50 healthy volunteers and 104 people with different types of lung cancer.

They tested for autoantibodies - immune system proteins directed at the body's own tissues in response to specific chemical signals in the body.

They looked in particular for a panel of seven autoantibodies, which are associated with 'solid tumours,' such a lung, breast, ovarian, and prostate cancers, and triggered when cancerous changes are taking place.

They found the presence of all seven autoantibodies, and very high levels of at least one of the seven in almost eight out of 10 samples taken from patients with confirmed lung cancer.

And these autoantibodies were found in eight out of the nine patients whose cancer had not infiltrated the lymph nodes, the body's gatekeepers.

This indicates that the disease had not yet spread elsewhere and offers an 80% chance of a cure.

Only one healthy volunteer had more than one of these autoantibodies in their blood.

Other research has indicated that these autoantibodies can be picked up as early as five years before clinical symptoms start to show.

In a previous study, the researchers found abnormally high levels of specific autoantibodies in patients with breast cancer, prompting them to suggest that a test for these could be added to the screening programme. That study also showed that these autoantibodies were present before clinical symptoms appeared..

The authors argue that the lungs are especially sensitive to radiation, so repeated chest x-rays are not ideal for picking up lung cancer.

A blood test, on the other hand, is cheap compared with imaging techniques, and has no side effects. And the panel can be changed to include more or different autoantibodies for lung and other cancers.

They suggest that the blood test could be used for people at increased risk of developing the disease, such as smokers and passive smokers.

If they test positive, these people could then be referred for more detailed scans, such as computed tomography (CT) or magnetic resonance imaging (MRI), they suggest.
-end-


BMJ

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.